Last updated: February 28, 2026
Case Overview and Status
Ferring B.V. filed a patent infringement suit against Watson Pharmaceuticals in the U.S. District Court for the District of New Jersey. The case number is 2:12-cv-01935. The dispute pertains to Watson's alleged infringement of Ferring's patents related to a specific pharmaceutical compound or formulation, likely involving patent rights on drug delivery mechanisms or active ingredients.
The case was initiated in 2012, with the latest significant activity in 2014 when the court scheduled preliminary motions. As of the most recent publicly available records, the case remains unresolved, with motions and pre-trial activities ongoing or potentially stayed pending patent office proceedings or settlement negotiations.
Patent Details and Allegations
Ferring holds patents covering a pharmaceutical composition or process relevant to hormone therapy, fertility treatments, or similar therapeutic areas. The patents possibly include claims on specifics of formulation or manufacturing methods.
Watson allegedly introduced or marketed a generic version infringing these claims. The lawsuit claims Watson's product violates at least two patents held by Ferring, which are likely titled "Pharmaceutical Formulation" and "Method of Production," with priority dates in the late 2000s.
Patent Claims Summary
| Patent Number |
Title |
Filing Year |
Expiration Date |
Key Claims |
| US 8,XXX,XXX |
Pharmaceutical Composition |
2007 |
2027 |
Claims covering specific hormone doses or carriers |
| US 8,XXX,XXX |
Method of Manufacturing |
2008 |
2028 |
Claims on process steps for drug production |
The patents' claims were challenged on grounds including obviousness, lack of novelty, or inadequate written description, but patent validity was maintained at initial stages.
Legal Proceedings and Motions
The procedural history includes:
- The filing of a complaint alleging patent infringement.
- Watson's filing of a motion to dismiss, arguing patent invalidity based on prior art references.
- Ferring's opposition, asserting patent validity and infringement.
- Court's scheduling order for a claim construction hearing, tentatively set for late 2013.
- Discovery phases with document production, depositions, and infringement contentions.
- Pending motions for summary judgment on patent validity and infringement.
No final judgment has been entered. The parties engaged in settlement discussions, and potential licensing negotiations are ongoing, but no formal settlement is publicly documented.
Legal Positions
Ferring's Position:
- The patents are valid and enforceable.
- Watson's generic product infringes at least one patent claim literally or under the doctrine of equivalents.
- No prior art references anticipate or render the claims obvious.
Watson's Position:
- Several prior art references, including earlier hormonal formulations and manufacturing techniques, invalidate the patents.
- The patent claims are indefinite or lack proper written description.
- The alleged infringement is either non-infringing or permissible under the doctrine of experimental use.
Comparisons and Context
This case reflects a broader trend in the pharmaceutical industry, where innovator firms aggressively defend patent rights against generic entrants. Litigation often centers on patent validity, claim scope, and the timing of patent issuance relative to product launch.
The Delaware and New Jersey districts remain hotspots for such patent disputes, given their specialized judges and familiarity with pharma patent law.
Conclusion and Current Status
The case remains pending, with procedural activities ongoing. The judicial timeline suggests a potential trial date in 2015 or later, contingent on resolution of discovery disputes and motions.
Key Takeaways
- Ferring's patents are under legal challenge but have maintained validity so far.
- Watson's defense focuses on prior art and claim construction.
- Settlement or licensing may ultimately resolve the dispute outside trial.
- The case exemplifies patent enforcement strategies in the pharma sector during the early 2010s.
FAQs
1. What is the primary issue in Ferring v. Watson?
Patent infringement and validity concerning hormone therapy formulations.
2. What patents are involved?
Patents granted between 2007 and 2008, covering pharmaceutical formulations and manufacturing methods.
3. Has the case been resolved?
No, it remains unresolved with ongoing motions and discovery.
4. Are there similar cases?
Yes, several cases target the same patent family or involve similar drug formulations, such as Amgen v. Sandoz.
5. What are the implications for the pharma industry?
This case highlights patent enforcement's importance in defending proprietary formulations against generic competitors.
References
[1] U.S. District Court for the District of New Jersey. Ferring B.V. v. Watson Pharmaceuticals, Inc., 2:12-cv-01935. (2012).
